Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 8
2004 4
2005 5
2006 3
2007 8
2008 9
2009 10
2010 13
2011 9
2012 17
2013 16
2014 18
2015 21
2016 24
2017 13
2018 11
2019 18
2020 10
2021 14
2022 12
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ishida t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: ishida t. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
FE65 in breast cancer and its clinicopathological significance.
Xu J, Iwabuchi E, Miki Y, Kanai A, Ishida T, Sasano H. Xu J, et al. Among authors: ishida t. Breast Cancer. 2022 Jan;29(1):144-155. doi: 10.1007/s12282-021-01291-4. Epub 2021 Sep 8. Breast Cancer. 2022. PMID: 34498219
Intracrine mechanism of estrogen synthesis in breast cancer.
Suzuki T, Moriya T, Ishida T, Ohuchi N, Sasano H. Suzuki T, et al. Among authors: ishida t. Biomed Pharmacother. 2003 Dec;57(10):460-2. doi: 10.1016/j.biopha.2003.09.007. Biomed Pharmacother. 2003. PMID: 14637389 Review.
217 results